-
FDA Accepts Breyanzi sBLA from Bristol Myers Squibb and Grants It Priority Review for MZL
07 Aug 2025 02:30 GMT
… for Hematology and Cell Therapy, Bristol Myers Squibb, in a company press … Strategies (2) program for Bristol Myers Squibb’s liso-cel (Breyanzi) to … , and Canada.
References
1. Bristol Myers Squibb. Bristol Myers Squibb’s Application for Breyanzi …
-
US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL
06 Aug 2025 14:58 GMT
… for haematology and cell therapy, Bristol Myers Squibb. “This FDA acceptance brings … lines of systemic therapy.
Bristol Myers Squibb’s clinical development program for … leader in cell therapy, Bristol Myers Squibb is uniquely positioned to unlock …
-
FDA Grants Priority Review to Bristol Myers Squibb’s Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma
06 Aug 2025 12:58 GMT
… granted Priority Review status to Bristol Myers Squibb’s (BMS) supplemental Biologics … for approved indications.”3
References
Bristol Myers Squibb’s Application for Breyanzi … ?term=(NCT04245839)&rank=1
Bristol Myers Squibb Presents First Data from …
-
Bristol Myers: priority review for MZL lymphoma
06 Aug 2025 11:22 GMT
Bristol Myers Squibb has announced that the FDA …
-
Bristol Myers Squibb Breyanzi application accepted for priority review by USFDA for Marginal Zone Lymphoma
06 Aug 2025 06:53 GMT
Princeton: Bristol Myers Squibb has announced that the U. … for Hematology and Cell Therapy, Bristol Myers Squibb. “This FDA acceptance brings …
-
Bristol-Myers Squibb: Declines Have Gone Too Far
02 Aug 2025 18:19 GMT
Bristol-Myers Squibb's sales are stabilizing, … rate it a buy.
JHVEPhoto Bristol-Myers Squibb Company (NYSE:BMY) has …
-
Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025
02 Aug 2025 08:03 GMT
… the strength of Cobenfy. Bristol-Myers Squibb (BMY) Sees Healthy Momentum … with pharmaceutical drugs awaiting distribution. Bristol-Myers Squibb Company (NYSE:BMY) increased … with foreign exchange rates. Bristol-Myers Squibb Company (NYSE:BMY) expects …
-
Bristol Myers Squibb presents new PROTACs for autoimmune and inflammatory disorders
02 Aug 2025 03:28 GMT
Immune
Bristol Myers Squibb Co. has prepared and tested …
-
Bristol-Myers Squibb Company (NYSE:BMY) Q2 2025 Earnings Call Transcript
01 Aug 2025 14:05 GMT
… Transcript July 31, 2025
Bristol-Myers Squibb Company beats earnings expectations. … Session
Follow Bristol Myers Squibb Co (NYSE:BMY) Follow Bristol Myers Squibb Co ( … disconnect.
Follow Bristol Myers Squibb Co (NYSE:BMY) Follow Bristol Myers Squibb Co (NYSE …
-
FDA Accepts Breyanzi sBLA for Relapsed Marginal Zone Lymphoma
07 Aug 2025 01:09 GMT
… for Hematology and Cell Therapy, Bristol Myers Squibb, said in the news … more aggressive form.
Reference
“Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene … Refractory Marginal Zone Lymphoma (MZL),” Bristol Myers Squibb. News Release. Aug. 4 …
About
© 1995-2025